OncoMatch/Clinical Trials/NCT06984146
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
Is NCT06984146 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Nivolumab and Doxorubicin for hodgkin lymphoma, adult.
Treatment: Nivolumab · Doxorubicin · Vinblastine · Dacarbazine — The aim of the current trial is to evaluate the efficacy and safety of flat-dose nivolumab (40 mg) in combination with AVD in the management of patients with newly diagnosed advanced classic Hodgkin Lymphoma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Hodgkin Lymphoma
Disease stage
Required: Stage IIB, III, IV
Performance status
ECOG 0–4(Completely disabled)
Prior therapy
Lab requirements
Kidney function
creatinine <= 2x uln
Liver function
alt or ast <= 5x uln; bilirubin <= 2x uln
Cardiac function
ejection fraction > 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06984146 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage IIB or III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages